Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 Injection Approved to Initiate Clinical Trials

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company"), received the Drug Clinical Trial Approval Notice for SHR-1139 Injection approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), and will initiate clinical trials in the near future. SHR-1139 Injection is a bispecific antibody independently developed by the Company that simultaneously targets IL-23p19 and IL-36R, blocking both pathways at the same time and potentially providing more comprehensive and durable inflammation control. Upon review, no similar drugs have been approved for marketing domestically or internationally to date. As of now, the cumulative R&D investment in the SHR-1139 Injection-related project is approximately RMB162.70 million (unaudited).